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Abstract
Background: Reintubation is associated with high mortality. Identification of methods to avoid reintubation is
needed. The aim of this study was to assess whether prophylactic noninvasive ventilation (NIV) would benefit
patients with various cough strengths.
Methods: We prospectively enrolled 356 patients who successfully passed a spontaneous breathing trial in a
respiratory intensive care unit. Before extubation, cough peak flow was measured. After extubation, attending
physicians determined whether the patients would receive prophylactic NIV or conventional oxygen treatment
(control group). Patients were followed up to 90 days postextubation or death, whichever came first.
Results: The median value of cough peak flow was 70 L/minute. Among the patients with cough peak
flow ≤70 L/minute, 108 received NIV and 72 received conventional oxygen treatment. In this cohort, NIV reduced
reintubation (9 % vs. 35 % at postextubation 72 h, p < 0.01; and 24 % vs. 49 % at postextubation 7 days, p < 0.01) and
postextubation 90-day mortality (43 % vs. 61 %, p = 0.02) compared with the control group. Further, use of NIV was an
independent protective factor for reintubation (OR = 0.19, p < 0.01 at 72 h postextubation; and OR = 0.33, p < 0.01 at
7 days postextubation) and for death at 90 days postextubation (OR = 0.40, p = 0.02). Among patients with cough peak
flow >70 L/minute, 71 received NIV and 105 received conventional oxygen treatment. In this cohort, NIV did not
reduce reintubation (6 % vs. 6 % at 72 h postextubation, p > 0.99; and 9 % vs. 9 % at 7 days postextubation, p > 0.99)
or postextubation 90-day mortality (21 % vs. 15 %, p = 0.32) compared with the control group. Further, use of NIV was
not associated with reintubation or postextubation 90-day mortality.
Conclusion: In a planned extubated population, prophylactic NIV benefited patients with weak cough but possibly not
in patients with strong cough.
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Background
Cough strength has been widely used to manage patients
being removed from mechanical ventilation after a suc-
cessful weaning test [1–6]. It is positively correlated with
respiratory muscle strength [7]. Patients with weak
cough are more likely to experience reintubation [1–6],
and reintubation is associated with an eightfold increase
in nosocomial pneumonia and a fivefold increase in
death [8, 9]. Thus, it is necessary to identify effective
methods to avoid reintubation.
Immediate use of prophylactic noninvasive ventilation
(NIV) after extubation reduces reintubation in patients
at high risk for extubation failure [10–13]. However, only
one study enrolled patients with weak cough [13]. In
that study, the authors enrolled only two patients with
weak cough in the NIV group and three in the control
group [13]. With such a small sample size, they failed to
demonstrate the efficacy of prophylactic NIV in patients
with weak cough. Further, to the best of our knowledge,
no study to date has reported the efficacy of NIV in pa-
tients with strong cough. Therefore, the aim of this
* Correspondence: duanjun412589@163.com
Department of Respiratory Medicine, First Affiliated Hospital of Chongqing
Medical University, Youyi Road 1, Yuzhong District, Chongqing 400016,
People’s Republic of China
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Duan et al. Critical Care  (2016) 20:316 
DOI 10.1186/s13054-016-1493-0
study was to determine whether prophylactic NIV would
benefit patients with various cough strengths.
Methods
The institutional review board of the First Affiliated
Hospital of Chongqing Medical University approved this
study. We prospectively enrolled patients who were
scheduled for extubation after a successful spontaneous
breathing trial (SBT) in a respiratory intensive care unit
(ICU). We excluded patients younger than 18 years of
age, with presence of a tracheostomy, or who refused to
participate. Before enrollment, we obtained informed
consent from the participants or their family members.
We managed the patients per our hospital’s protocols [6].
Every morning, we assessed each patient with regard to
whether he or she met the criteria for removal of mechan-
ical ventilation. We undertook an SBT if the following cri-
teria were met: improvement or resolution of the
underlying cause of acute respiratory failure, correction of
arterial hypoxemia (ratio of partial pressure of arterial oxy-
gen to fraction of inspired oxygen [PaO2/FiO2] ≥150,
positive end-expiratory pressure ≤5 cmH2O), body
temperature ≤38 °C, respiratory rate ≤30 breaths/mi-
nute, heart rate ≤120 beats/minute, and hemodynamic
stability [14, 15]. The SBT was carried out in pressure
support ventilation mode for 120 minutes. The support
pressure was set at 6 cmH2O for an endotracheal tube
inner diameter ≥7.5 mm and at 8 cmH2O for an endo-
tracheal tube inner diameter <7.5 mm [14, 16]. We de-
fined failure of the SBT as the presence one of the
following criteria: respiratory rate ≥35 breaths/minute; fre-
quency/tidal volume (rapid shallow breathing index) >105;
peripheral oxygen saturation (SpO2) <90 % at FiO2 ≥ 0.5;
heart rate ≥140 or ≤50 beats/minute; systolic blood pres-
sure ≥180 or ≤90 mmHg; diminishing consciousness or
diaphoresis; and clinical signs indicating respiratory
muscle fatigue, labored breathing, or both. If no signs
of SBT failure appeared after 120 minutes, the extu-
bation was performed at the discretion of the attend-
ing physicians.
Before extubation, we recorded data for physiological
variables, including Glasgow Coma Scale score. At the
same time, from the nurse recording sheet, we recorded
the suction frequency and volume of secretions preced-
ing 24 h of extubation. We also measured the cough
peak flow using a portable spirometer (Chestgraph
HI-101; Chest M.I., Tokyo, Japan) [6]. Before measure-
ment, we elevated the head of the bed to 30–45 degrees,
cleared the airway secretions by suction, and oxygenated
the patient with 100 % oxygen for 2 minutes. Next, we dis-
connected the ventilator, connected the spirometer to the
endotracheal tube, and coached the patient to cough with
as much effort as possible. We measured coughs three
times, and the highest value was chosen. To avoid bias,
the attending physicians were blind to the value of cough
peak flow. Cough peak flow less than the median value
was defined as weak cough.
After extubation, the attending physician determined
whether the patient received prophylactic NIV or con-
ventional oxygen treatment. We did not predefine the
criteria for NIV. However, patients with weak hand-grip
strength, high partial pressure of carbon dioxide in arter-
ial blood, high Acute Physiology and Chronic Health
Evaluation II score, low PaO2, and small volume of se-
cretions were more likely to be ordered to receive
prophylactic NIV. Prophylactic NIV (BiPAP Vision or
V60; Philips Respironics, Monroeville, PA, USA) was im-
mediately used after extubation. The face mask was the
first choice. The appropriate size of the mask was se-
lected according to the patient’s facial type. If a patient
did not tolerate a face mask, a nasal mask was tried. The
parameters of the ventilator were adjusted as follows.
Expiratory positive airway pressure was set at 4–6
cmH2O. Inspiratory positive airway pressure was ad-
justed by increments of 1–2 cmH2O to obtain a tidal
volume of around 8 ml/kg or to the maximum tolerated
level for each patient. Usually, the inspiratory positive
airway pressure was maintained at 12–20 cmH2O. FiO2
was set to maintain SpO2 at around 95 %. After 24 h,
weaning from NIV was considered according to hospital
protocol [17].
Reintubation was also determined by attending physi-
cians on the basis of the following indicators (one major
criterion or at least two minor criteria). The major criteria
were (1) respiratory arrest, (2) loss of consciousness, (3)
heart rate <50 beats/minute with loss of alertness, (4) de-
velopment of conditions necessitating intubation to protect
the airway (coma or seizure disorders) or copious tracheal
secretions requiring management, and (5) hemodynamic
instability without response to fluids and vasoactive drugs.
The minor criteria were (1) respiratory rate >35 breaths/
minute, (2) pH <7.35 for hypoxemic patients and <7.30 for
hypercapnic patients, (3) PaO2 < 60 mmHg at FiO2 > 0.5 or
supplemental oxygen flow >10 L/minute, (4) persistent
tachycardia, and (5) persistent activation of accessory re-
spiratory muscles.
We recorded whether the patient was reintubated
within 72 h and within 7 days postextubation. We also
recorded the duration of ICU stay, duration of hospital
stay, duration of postextubation ICU stay, and duration
of postextubation hospital stay when a patient was dis-
charged from or died in the hospital. We followed the
patient up to 90 days postextubation or death, whichever
came first.
SPSS version 17.0 software (SPSS, Chicago, IL, USA)
was used to analyze the data. Mean and SD values were
used to report normally distributed continuous variables.
The difference in two groups was analyzed using an
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unpaired Student’s t test. Median and interquartile range
values were used to report non-normally distributed
continuous variables. The difference between two groups
was analyzed with the Mann–Whitney U test. For
grouped data, the chi-square and/or Fisher’s exact test
was used. The cumulative 90-day survival probability
was analyzed by creating Kaplan-Meier curves, and
the difference between two groups was analyzed by
log-rank test. p < 0.05 was considered to signify statis-
tical significance.
Results
We enrolled 356 patients in this study between January
2011 and May 2016. The median value of cough peak flow
was 70 L/minute. The proportions of patients who
received NIV were 60 % (108 of 180 patients) among
those with cough peak flow ≤70 L/minute and 40 %
(71 of 176 patients) among those with cough peak
flow >70 L/minute. The demographics of the patients
are summarized in Table 1.
In patients with cough peak flow ≤70 L/minute, NIV
reduced reintubation at 72 h postextubation (10 of 108
[9 %] vs. 25 of 72 [35 %], p < 0.01) and 7 days postextu-
bation (26 of 108 [24 %] vs. 35 of 72 [49 %], p < 0.01)
compared with the control group (Table 2). It also re-
duced postextubation 90-day mortality (46 of 108 [43 %]
vs. 44 of 72 [61 %], p = 0.02). In addition, NIV was a pro-
tective factor for reintubation at 72 h and 7 days postex-
tubation (OR = 0.19, p < 0.01; OR = 0.33, p < 0.01)
(Table 3). It also was a protective factor for death at
Table 1 Baseline values between groups
Cough peak flow ≤70 L/minute Cough peak flow >70 L/minute
NIV (n = 108) Control (n = 72) p Valuea NIV (n = 71) Control (n = 105) p Valuea p Valueb
Age, years 73 ± 12 74 ± 13 0.68 67 ± 14 58 ± 19 <0.01c <0.01c
Females/males, n 32/76 33/39 0.04c 12/59 27/78 0.20 <0.01c
Reason for intubation
AECOPD 74 31 <0.01c 46 26 <0.01c <0.01c
Pneumonia 26 32 0.01c 13 36 0.03c 0.42
ARDS 2 5 0.12 9 22 0.23 <0.01c
Asthma 2 0 0.52 1 5 0.40 0.17
Other 4 4 0.72 2 16 0.01c 0.04c
APACHE II score
Upon admission 24 ± 6 23 ± 6 0.46 21 ± 6 19 ± 7 0.02c <0.01c
At extubation 13 ± 3 13 ± 3 0.65 12 ± 3 11 ± 3 0.02c <0.01c
Intubation period before extubation, days 8 ± 12 7 ± 5 0.44 7 ± 5 5 ± 4 <0.01c 0.01c
Cough peak flow, L/minute 48 ± 14 44 ± 15 0.07 98 ± 34 108 ± 29 0.04c <0.01c
Hemoglobin, g/dl 10.8 ± 2.3 10.4 ± 2.2 0.26 11.3 ± 2.5 11.3 ± 2.4 0.97 0.01c
Secretions, ml/24 h 75 ± 45 85 ± 54 0.18 72 ± 49 77 ± 73 0.61 0.56
Suction frequency/24 h 11 ± 4 13 ± 4 <0.01c 12 ± 4 12 ± 4 0.71 0.96
GCS score 14.7 ± 1.2 14.2 ± 1.8 0.06 14.9 ± 0.1 14.9 ± 0.1 0.80 <0.01c
Physiological parameters at extubation
pH 7.42 ± 0.05 7.43 ± 0.05 0.30 7.45 ± 0.05 7.46 ± 0.05 0.25 <0.01c
PaCO2, mmHg 51 ± 13 45 ± 13 <0.01
c 48 ± 11 39 ± 10 <0.01c <0.01c
PaO2/FiO2 222 ± 63 269 ± 86 <0.01
c 225 ± 55 265 ± 94 <0.01c 0.33
Respiratory rate, breaths/minute 23 ± 5 23 ± 5 0.65 23 ± 6 22 ± 5 0.09 0.44
Rapid shallow breathing index 60 ± 27 66 ± 24 0.12 55 ± 21 48 ± 23 0.06 <0.01c
Heart rate, beats/minute 99 ± 16 93 ± 16 0.02c 100 ± 17 94 ± 15 0.01c 0.96
Mean arterial pressure, mmHg 93 ± 13 90 ± 12 0.18 94 ± 12 93 ± 12 0.53 0.40
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, NIV Noninvasive ventilation, AECOPD Acute exacerbation of chronic obstructive
pulmonary disease, ARDS Acute respiratory distress syndrome, GCS Glasgow Coma Scale, PaCO2 Partial pressure of carbon dioxide in arterial blood, PaO2/FiO2 Ratio
of partial pressure of arterial oxygen to fraction of inspired oxygen
aDifference in NIV versus control
bDifference in weak versus strong cough
cp < 0.05
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90 days postextubation (OR = 0.40, p = 0.02). Further-
more, patients in the NIV group had higher survival
within 90 days postextubation (p = 0.03 by log-rank test)
(Fig. 1).
In patients with cough peak flow >70 L/minute, NIV
did not reduce reintubation (at 72 h postextubation: 4 of
71 [6 %] vs. 6 of 105 [6 %], p > 0.99; 7 days postex-
tubation: 6 of 71 [9 %] vs. 9 of 105 [9 %], p > 0.99) or
postextubation 90-day mortality (15 of 71 [21 %] vs. 16
of 105 [15 %], p = 0.32) compared with the control group
(Table 2), nor was NIV associated with reintubation or
postextubation 90-day mortality (Table 3). In addition,
survival rates within 90 days postextubation were similar
between the two groups (p = 0.32 by log-rank test)
(Fig. 2).
The subgroup analysis of patients with chronic ob-
structive pulmonary disease (COPD) is summarized in
Table 4. Prophylactic NIV was a protective factor for
reintubation at 72 h postextubation (OR = 0.11, p < 0.01)
and 7 days postextubation (OR = 0.27, p = 0.01) in patients
Table 2 Outcomes between groups
Cough peak flow ≤70 L/minute Cough peak flow >70 L/minute
NIV (n = 108) Control (n = 72) p Valuea NIV (n = 71) Control (n = 105) p Valuea p Valueb
Duration of ICU stay, days 13 (10–20) 15 (9–26) 0.34 12 (8–18) 9 (5–12) <0.01c <0.01c
Duration of hospital stay, days 23 (14–37) 26 (15–48) 0.16 19 (12–28) 17 (12–26) 0.40 <0.01c
Duration of postextubation ICU stay, days 6 (4–11) 7 (3–18) 0.52 5 (3–9) 3 (1–6) <0.01c <0.01c
Duration of postextubation hospital stay, days 13 (7–23) 14 (6–26) 0.78 10 (7–17) 10 (6–16) 0.54 <0.01c
Reintubation at 72 h postextubation 10 (9 %) 25 (35 %) <0.01c 4 (6 %) 6 (6 %) >0.99 <0.01c
Reintubation at 7 days postextubation 26 (24 %) 35 (49 %) <0.01c 6 (9 %) 9 (9 %) >0.99 <0.01c
Hospital mortality 36 (33 %) 33 (46 %) 0.12 8 (11 %) 14 (13 %) 0.82 <0.01c
Postextubation 90-day mortality 46 (43 %) 44 (61 %) 0.02c 15 (21 %) 16 (15 %) 0.32 <0.01c
ICU Intensive care unit, NIV Noninvasive ventilation
aDifference between NIV and control
bDifference between weak and strong cough
cp < 0.05
Table 3 Multivariable analysis to identify independent risk factors for reintubation at 72 h and 7 days postextubation, and for death
at 90 days postextubation
Cough peak flow ≤70 L/minute Cough peak flow >70 L/minute
OR (95 % CI) p Value OR (95 % CI) p Value
Reintubation at 72 h postextubation
Use of NIV 0.19 (0.09–0.43) <0.01 – N/A
APACHE II score at extubation – N/A 1.34 (1.10–1.63) <0.01
Reintubation at 7 days postextubation
Use of NIV 0.33 (0.16–0.66) <0.01 – N/A
Intubation period before extubation, days 1.07 (1.01–1.13) 0.02 – N/A
Hemoglobin, g/dl 0.98 (0.96–0.99) 0.01 0.96 (0.94–0.99) 0.01
Cough peak flow, L/minute 0.97 (0.95–1.00) 0.04 – N/A
APACHE II score at extubation – N/A 1.30 (1.08–1.56) <0.01
Death at 90 days postextubation
Use of NIV 0.40 (0.19–0.85) 0.02 – N/A
Hemoglobin, g/dl 0.97 (0.95–0.99) <0.01 0.97 (0.95–0.99) <0.01
Cough peak flow, L/minute 0.96 (0.94–0.99) <0.01 – N/A
APACHE II score at extubation 1.18 (1.04–1.33) 0.01 1.37 (1.17–1.60) <0.01
Abbreviations: NIV Noninvasive ventilation, APACHE II Acute Physiology and Chronic Health Evaluation II, N/A Not applicable
We entered age, sex, APACHE II score, intubation period, cough peak flow, hemoglobin, secretions, suction frequency, Glasgow Coma Scale score, heart rate,
respiratory rate, rapid shallow breathing index, arterial blood gas tests, and use of NIV into multivariable analysis to identify independent risk factors for
reintubation at 72 h and 7 days postextubation, and for death at 90 days postextubation
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with cough peak flow ≤70 L/minute. It was also a protect-
ive factor for death at postextubation 90 days in patients
with weak cough (OR = 0.27, p = 0.01). However, prophy-
lactic NIV was not associated with reintubation or postex-
tubation 90-day mortality in patients with cough peak
flow >70 L/minute.
Discussion
To the best of our knowledge, this is the first study to
report the efficacy of NIV in preventing reintubation in
patients with weak cough strength (<70 L/minute). It
also shows that when cough strength was >70 L/minute,
reintubation was rare and NIV was not needed.
Respiratory muscle function is associated with ventila-
tor weaning. Patients with greater respiratory muscle
strength are more likely to wean from mechanical venti-
lation [18, 19], and respiratory muscle strength is posi-
tively correlated with cough peak flow [7]. Therefore,
cough peak flow can serve as a predictor for successful
weaning from mechanical ventilation. Several studies
have reported that patients with lower cough peak flow
had higher probability of reintubation [1–6]. However,
how to reduce or avoid reintubation in this population is
still unclear.
NIV reduces the work of breathing in patients with
acute respiratory failure [20]. Given the advantages of
NIV, it has been widely used in postextubation periods
[10–13, 21, 22]. However, NIV benefited neither the en-
tire population nor an unselected COPD population
when it was used immediately after extubation [21, 22],
but immediate use of NIV after extubation benefited pa-
tients at high risk for reintubation [10–13]. In our
present study, we demonstrate that prophylactic NIV
benefited patients with weak cough, including the COPD
population, but that it did not benefit patients with
strong cough with or without COPD. The results of this
study may help practitioners to improve postextubation
management.
To our knowledge, only one other study to date has
been aimed at demonstrating the efficacy of prophylactic
NIV in a high-risk population that included patients
with weak cough [13]. In that study, the authors enrolled
only five patients with weak cough. With such a small
sample size, they failed to demonstrate the efficacy of
prophylactic NIV in patients with weak cough. Further,
they assessed the cough strength using Airway Care
Score (a semiquantitative scale that includes six dimen-
sions). However, cough peak flow is objective and has
been widely used in cough strength assessment [1–6].
So, we selected a more objective and widely accepted
measure to assess cough strength, which may be much
easier to use in guiding clinical practitioners to manage
ventilator weaning.
Fig. 1 Cumulative 90-day survival in patients with cough peak
flow ≤70 L/minute. NIV Noninvasive ventilation
Fig. 2 Cumulative 90-day survival in patients with cough peak
flow >70 L/minute. NIV Noninvasive ventilation
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In patients with cough peak flow >70 L/minute,
prophylactic NIV did not reduce reintubation or postex-
tubation 90-day mortality. It indicated that patients with
strong cough possibly received no benefit from prophy-
lactic NIV. However, use of a high-flow nasal cannula
benefited low-risk patients when it was used immedi-
ately after planned extubation [23]. Further, compared
with NIV, it also showed benefits in patients with acute
respiratory failure [24]. Thus, a high-flow nasal cannula
was a good choice for postextubation management in
patients with strong cough.
Our study may be limited by the methodology we
used. It was an observational study, and the attending
physicians determined whether the patients received
NIV or conventional oxygen treatment. Patients with
more serious illness were more likely to receive NIV.
This led to unequal demographics between the NIV and
control groups. However, we used multivariable logistic
regression analysis and found that NIV was a protective
factor for reintubation and for death at 90 days postex-
tubation in patients with weak cough. Although a cohort
study has less evidentiary strength than a randomized
controlled study, our study with a large sample size
shows the efficacy of prophylactic NIV in patients with
weak cough strength.
Conclusions
The median value of cough peak flow was 70 L/minute
in a large planned extubation population. Prophylactic
NIV benefited patients with weak cough with or without
COPD, but not in patients with strong cough.
Key messages
 The median value of cough peak flow in the planned
extubated population was 70 L/minute.
 Immediate use of NIV after extubation reduced
reintubation and postextubation 90-day mortality in
patients with weak cough.
 However, prophylactic NIV may not have benefited
patients with strong cough.
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